BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22365399)

  • 41. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas.
    Yu R; Chen G; Zhou C; Gao Z; Shi Y; Shi Y; Zhou X; Xie J; Liu H; Gong L
    Leuk Res; 2012 Sep; 36(9):1141-6. PubMed ID: 22726922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
    Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
    Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Expression of ALK protein in large cell lymphoma with ALCL chromosome translocation in relation to prognosis].
    Ji TH; Li HL; Jiang HY; Zhao T; Yu YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):543-6. PubMed ID: 18549625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prognostic significance of the NPM-ALK fusion gene in bone marrow and peripheral blood for patients with anaplastic large cell lymphoma].
    Yang J; Zhao XX; Jin L; Duan YL; Huang S; Zhang M; Zhang R; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):700-3. PubMed ID: 23978023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
    K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
    Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
    Falini B; Bigerna B; Fizzotti M; Pulford K; Pileri SA; Delsol G; Carbone A; Paulli M; Magrini U; Menestrina F; Giardini R; Pilotti S; Mezzelani A; Ugolini B; Billi M; Pucciarini A; Pacini R; Pelicci PG; Flenghi L
    Am J Pathol; 1998 Sep; 153(3):875-86. PubMed ID: 9736036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
    Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
    Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anaplastic large cell lymphoma in children and adolescents.
    Lowe EJ; Gross TG
    Pediatr Hematol Oncol; 2013 Sep; 30(6):509-19. PubMed ID: 23758281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma.
    Lae ME; Ahmed I; Macon WR
    Am J Clin Pathol; 2002 Nov; 118(5):773-9. PubMed ID: 12428799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
    Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
    Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
    Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
    Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas.
    Bovio IM; Allan RW
    Am J Clin Pathol; 2008 Oct; 130(4):628-34. PubMed ID: 18794057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
    Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
    Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The heterogeneous landscape of ALK negative ALCL.
    Mereu E; Pellegrino E; Scarfò I; Inghirami G; Piva R
    Oncotarget; 2017 Mar; 8(11):18525-18536. PubMed ID: 28061468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease.
    Fan G; Kotylo P; Neiman RS; Braziel RM
    Am J Clin Pathol; 2003 Feb; 119(2):199-204. PubMed ID: 12579989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Meijer CJ
    J Pathol; 2003 May; 200(1):4-15. PubMed ID: 12692835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.